ClinicaliQ Trial Snapshot
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. — Active Not Recruiting • Phase II • Infectious Disease • NCT05461170.
- Two new drugs tested together in hepatitis D patients to check if they're safe and effective.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy Conditions: Hepatitis D, Chronic Interventions: VIR-2218, VIR-3434, NRTI Lead Sponsor: Vir Biotechnology, Inc. Planned Enrollment: 95 participants